KDM8/JMJD5 as a dual coactivator of AR and PKM2 integrates AR/EZH2 network and tumor metabolism in CRPC

Hung Jung Wang, Mamata Pochampalli, Ling Yu Wang, June X Zou, Pei Shan Li, Sheng Chieh Hsu, Bi Juan Wang, Shih Han Huang, Ping Yang, Joy C. Yang, Cheng Ying Chu, Chia Ling Hsieh, Shian Ying Sung, Chien Feng Li, Clifford G Tepper, David K. Ann, Allen C Gao, Christopher P Evans, Yoshihiro Izumiya, Chi Pin ChuuWen Ching Wang, Hongwu Chen, Hsing-Jien Kung

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

During the evolution into castration or therapy resistance, prostate cancer cells reprogram the androgen responses to cope with the diminishing level of androgens, and undergo metabolic adaption to the nutritionally deprived and hypoxia conditions. AR (androgen receptor) and PKM2 (pyruvate kinase M2) have key roles in these processes. We report in this study, KDM8/JMJD5, a histone lysine demethylase/dioxygnase, exhibits a novel property as a dual coactivator of AR and PKM2 and as such, it is a potent inducer of castration and therapy resistance. Previously, we showed that KDM8 is involved in the regulation of cell cycle and tumor metabolism in breast cancer cells. Its role in prostate cancer has not been explored. Here, we show that KDM8’s oncogenic properties in prostate cancer come from its direct interaction (1) with AR to affect androgen response and (2) with PKM2 to regulate tumor metabolism. The interaction with AR leads to the elevated expression of androgen response genes in androgen-deprived conditions. They include ANCCA/ATAD2 and EZH2, which are directly targeted by KDM8 and involved in sustaining the survival of the cells under hormone-deprived conditions. Notably, in enzalutamide-resistant cells, the expressions of both KDM8 and EZH2 are further elevated, so are neuroendocrine markers. Consequently, EZH2 inhibitors or KDM8 knockdown both resensitize the cells toward enzalutamide. In the cytosol, KDM8 associates with PKM2, the gatekeeper of pyruvate flux and translocates PKM2 into the nucleus, where the KDM8/PKM2 complex serves as a coactivator of HIF-1α to upregulate glycolytic genes. Using shRNA knockdown, we validate KDM8’s functions as a regulator for both androgen-responsive and metabolic genes. KDM8 thus presents itself as an ideal therapeutic target for metabolic adaptation and castration-resistance of prostate cancer cells.

Original languageEnglish (US)
JournalOncogene
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Pyruvate Kinase
Androgen Receptors
Androgens
Castration
Prostatic Neoplasms
Neoplasms
Histone Demethylases
Genes
Pyruvic Acid
Cytosol
Small Interfering RNA
Cell Survival
Cell Cycle
Up-Regulation
Therapeutics
Hormones
Breast Neoplasms

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

KDM8/JMJD5 as a dual coactivator of AR and PKM2 integrates AR/EZH2 network and tumor metabolism in CRPC. / Wang, Hung Jung; Pochampalli, Mamata; Wang, Ling Yu; Zou, June X; Li, Pei Shan; Hsu, Sheng Chieh; Wang, Bi Juan; Huang, Shih Han; Yang, Ping; Yang, Joy C.; Chu, Cheng Ying; Hsieh, Chia Ling; Sung, Shian Ying; Li, Chien Feng; Tepper, Clifford G; Ann, David K.; Gao, Allen C; Evans, Christopher P; Izumiya, Yoshihiro; Chuu, Chi Pin; Wang, Wen Ching; Chen, Hongwu; Kung, Hsing-Jien.

In: Oncogene, 01.01.2018.

Research output: Contribution to journalArticle

Wang, HJ, Pochampalli, M, Wang, LY, Zou, JX, Li, PS, Hsu, SC, Wang, BJ, Huang, SH, Yang, P, Yang, JC, Chu, CY, Hsieh, CL, Sung, SY, Li, CF, Tepper, CG, Ann, DK, Gao, AC, Evans, CP, Izumiya, Y, Chuu, CP, Wang, WC, Chen, H & Kung, H-J 2018, 'KDM8/JMJD5 as a dual coactivator of AR and PKM2 integrates AR/EZH2 network and tumor metabolism in CRPC', Oncogene. https://doi.org/10.1038/s41388-018-0414-x
Wang, Hung Jung ; Pochampalli, Mamata ; Wang, Ling Yu ; Zou, June X ; Li, Pei Shan ; Hsu, Sheng Chieh ; Wang, Bi Juan ; Huang, Shih Han ; Yang, Ping ; Yang, Joy C. ; Chu, Cheng Ying ; Hsieh, Chia Ling ; Sung, Shian Ying ; Li, Chien Feng ; Tepper, Clifford G ; Ann, David K. ; Gao, Allen C ; Evans, Christopher P ; Izumiya, Yoshihiro ; Chuu, Chi Pin ; Wang, Wen Ching ; Chen, Hongwu ; Kung, Hsing-Jien. / KDM8/JMJD5 as a dual coactivator of AR and PKM2 integrates AR/EZH2 network and tumor metabolism in CRPC. In: Oncogene. 2018.
@article{7cd46a97dd0741208e902e61bee0a4f8,
title = "KDM8/JMJD5 as a dual coactivator of AR and PKM2 integrates AR/EZH2 network and tumor metabolism in CRPC",
abstract = "During the evolution into castration or therapy resistance, prostate cancer cells reprogram the androgen responses to cope with the diminishing level of androgens, and undergo metabolic adaption to the nutritionally deprived and hypoxia conditions. AR (androgen receptor) and PKM2 (pyruvate kinase M2) have key roles in these processes. We report in this study, KDM8/JMJD5, a histone lysine demethylase/dioxygnase, exhibits a novel property as a dual coactivator of AR and PKM2 and as such, it is a potent inducer of castration and therapy resistance. Previously, we showed that KDM8 is involved in the regulation of cell cycle and tumor metabolism in breast cancer cells. Its role in prostate cancer has not been explored. Here, we show that KDM8’s oncogenic properties in prostate cancer come from its direct interaction (1) with AR to affect androgen response and (2) with PKM2 to regulate tumor metabolism. The interaction with AR leads to the elevated expression of androgen response genes in androgen-deprived conditions. They include ANCCA/ATAD2 and EZH2, which are directly targeted by KDM8 and involved in sustaining the survival of the cells under hormone-deprived conditions. Notably, in enzalutamide-resistant cells, the expressions of both KDM8 and EZH2 are further elevated, so are neuroendocrine markers. Consequently, EZH2 inhibitors or KDM8 knockdown both resensitize the cells toward enzalutamide. In the cytosol, KDM8 associates with PKM2, the gatekeeper of pyruvate flux and translocates PKM2 into the nucleus, where the KDM8/PKM2 complex serves as a coactivator of HIF-1α to upregulate glycolytic genes. Using shRNA knockdown, we validate KDM8’s functions as a regulator for both androgen-responsive and metabolic genes. KDM8 thus presents itself as an ideal therapeutic target for metabolic adaptation and castration-resistance of prostate cancer cells.",
author = "Wang, {Hung Jung} and Mamata Pochampalli and Wang, {Ling Yu} and Zou, {June X} and Li, {Pei Shan} and Hsu, {Sheng Chieh} and Wang, {Bi Juan} and Huang, {Shih Han} and Ping Yang and Yang, {Joy C.} and Chu, {Cheng Ying} and Hsieh, {Chia Ling} and Sung, {Shian Ying} and Li, {Chien Feng} and Tepper, {Clifford G} and Ann, {David K.} and Gao, {Allen C} and Evans, {Christopher P} and Yoshihiro Izumiya and Chuu, {Chi Pin} and Wang, {Wen Ching} and Hongwu Chen and Hsing-Jien Kung",
year = "2018",
month = "1",
day = "1",
doi = "10.1038/s41388-018-0414-x",
language = "English (US)",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - KDM8/JMJD5 as a dual coactivator of AR and PKM2 integrates AR/EZH2 network and tumor metabolism in CRPC

AU - Wang, Hung Jung

AU - Pochampalli, Mamata

AU - Wang, Ling Yu

AU - Zou, June X

AU - Li, Pei Shan

AU - Hsu, Sheng Chieh

AU - Wang, Bi Juan

AU - Huang, Shih Han

AU - Yang, Ping

AU - Yang, Joy C.

AU - Chu, Cheng Ying

AU - Hsieh, Chia Ling

AU - Sung, Shian Ying

AU - Li, Chien Feng

AU - Tepper, Clifford G

AU - Ann, David K.

AU - Gao, Allen C

AU - Evans, Christopher P

AU - Izumiya, Yoshihiro

AU - Chuu, Chi Pin

AU - Wang, Wen Ching

AU - Chen, Hongwu

AU - Kung, Hsing-Jien

PY - 2018/1/1

Y1 - 2018/1/1

N2 - During the evolution into castration or therapy resistance, prostate cancer cells reprogram the androgen responses to cope with the diminishing level of androgens, and undergo metabolic adaption to the nutritionally deprived and hypoxia conditions. AR (androgen receptor) and PKM2 (pyruvate kinase M2) have key roles in these processes. We report in this study, KDM8/JMJD5, a histone lysine demethylase/dioxygnase, exhibits a novel property as a dual coactivator of AR and PKM2 and as such, it is a potent inducer of castration and therapy resistance. Previously, we showed that KDM8 is involved in the regulation of cell cycle and tumor metabolism in breast cancer cells. Its role in prostate cancer has not been explored. Here, we show that KDM8’s oncogenic properties in prostate cancer come from its direct interaction (1) with AR to affect androgen response and (2) with PKM2 to regulate tumor metabolism. The interaction with AR leads to the elevated expression of androgen response genes in androgen-deprived conditions. They include ANCCA/ATAD2 and EZH2, which are directly targeted by KDM8 and involved in sustaining the survival of the cells under hormone-deprived conditions. Notably, in enzalutamide-resistant cells, the expressions of both KDM8 and EZH2 are further elevated, so are neuroendocrine markers. Consequently, EZH2 inhibitors or KDM8 knockdown both resensitize the cells toward enzalutamide. In the cytosol, KDM8 associates with PKM2, the gatekeeper of pyruvate flux and translocates PKM2 into the nucleus, where the KDM8/PKM2 complex serves as a coactivator of HIF-1α to upregulate glycolytic genes. Using shRNA knockdown, we validate KDM8’s functions as a regulator for both androgen-responsive and metabolic genes. KDM8 thus presents itself as an ideal therapeutic target for metabolic adaptation and castration-resistance of prostate cancer cells.

AB - During the evolution into castration or therapy resistance, prostate cancer cells reprogram the androgen responses to cope with the diminishing level of androgens, and undergo metabolic adaption to the nutritionally deprived and hypoxia conditions. AR (androgen receptor) and PKM2 (pyruvate kinase M2) have key roles in these processes. We report in this study, KDM8/JMJD5, a histone lysine demethylase/dioxygnase, exhibits a novel property as a dual coactivator of AR and PKM2 and as such, it is a potent inducer of castration and therapy resistance. Previously, we showed that KDM8 is involved in the regulation of cell cycle and tumor metabolism in breast cancer cells. Its role in prostate cancer has not been explored. Here, we show that KDM8’s oncogenic properties in prostate cancer come from its direct interaction (1) with AR to affect androgen response and (2) with PKM2 to regulate tumor metabolism. The interaction with AR leads to the elevated expression of androgen response genes in androgen-deprived conditions. They include ANCCA/ATAD2 and EZH2, which are directly targeted by KDM8 and involved in sustaining the survival of the cells under hormone-deprived conditions. Notably, in enzalutamide-resistant cells, the expressions of both KDM8 and EZH2 are further elevated, so are neuroendocrine markers. Consequently, EZH2 inhibitors or KDM8 knockdown both resensitize the cells toward enzalutamide. In the cytosol, KDM8 associates with PKM2, the gatekeeper of pyruvate flux and translocates PKM2 into the nucleus, where the KDM8/PKM2 complex serves as a coactivator of HIF-1α to upregulate glycolytic genes. Using shRNA knockdown, we validate KDM8’s functions as a regulator for both androgen-responsive and metabolic genes. KDM8 thus presents itself as an ideal therapeutic target for metabolic adaptation and castration-resistance of prostate cancer cells.

UR - http://www.scopus.com/inward/record.url?scp=85052531213&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052531213&partnerID=8YFLogxK

U2 - 10.1038/s41388-018-0414-x

DO - 10.1038/s41388-018-0414-x

M3 - Article

C2 - 30072740

AN - SCOPUS:85052531213

JO - Oncogene

JF - Oncogene

SN - 0950-9232

ER -